- Home
- PDT vs RGNX Comparison
PDT vs RGNX Comparison
Compare PDT & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PDT | RGNX |
|---|---|---|
| Founded | 1989 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 652.7M | 761.9M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | PDT | RGNX |
|---|---|---|
| Price | $13.42 | $8.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $29.13 |
| AVG Volume (30 Days) | 145.6K | ★ 1.2M |
| Earning Date | 01-01-0001 | 03-12-2026 |
| Dividend Yield | ★ 8.88% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $161,318,000.00 |
| Revenue This Year | N/A | $128.55 |
| Revenue Next Year | N/A | $47.33 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 91.30 |
| 52 Week Low | $8.77 | $5.04 |
| 52 Week High | $13.05 | $16.19 |
Technical Indicators
Market Signals| Indicator | PDT | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 71.15 | 24.98 |
| Support Level | $13.25 | $10.15 |
| Resistance Level | $13.28 | $8.63 |
| Average True Range (ATR) | 0.11 | 0.79 |
| MACD | 0.03 | -0.34 |
| Stochastic Oscillator | 89.83 | 8.28 |
Price Performance
Historical ComparisonAbout PDT John Hancock Premium Dividend Fund
John Hancock Premium Div Fund is a United States-based closed-end management investment company. It seeks to provide a high current income consistent with modest capital growth. The fund will pursue its objective by investing in a diversified portfolio comprised of dividend-paying preferred securities and common equity securities. The portfolio composition of the fund consists of preferred securities, common stocks, corporate bonds, capital preferred securities, and short-term investments.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.